The central gray matter, more precisely termed the periaqueductal gray (PAG), is a major structure in the midbrain gray matter surrounding the cerebral aqueduct. This region serves as a crucial hub for pain modulation, emotional processing, autonomic control, and defensive behaviors. The PAG integrates inputs from higher brain regions including the hypothalamus, amygdala, and prefrontal cortex to coordinate adaptive responses to threatening stimuli. In recent years, research has increasingly revealed the PAG's involvement in neurodegenerative diseases, particularly in pain processing abnormalities, emotional disturbances, and autonomic dysfunction observed in conditions such as Parkinson's disease, Alzheimer's disease, and Huntington's disease [1][2][3].
The PAG is organized into four longitudinal columns that wrap around the cerebral aqueduct:
¶ Columns
- Dorsolateral PAG (dlPAG): Associated with active coping behaviors and analgesia
- Lateral PAG (lPAG): Involved in emotional and cardiovascular responses
- Ventrolateral PAG (vlPAG): Primary site for opioid-mediated analgesia and fear responses
- Medial PAG (mPAG): Coordinates vocalization and reproductive behavior
The PAG contains diverse neuronal populations:
- Neurons: Medium-sized multipolar neurons, small interneurons
- Neurotransmitters: Glutamate (excitatory), GABA (inhibitory), serotonin (modulatory)
- Neuropeptides: Enkephalin, dynorphin, substance P, cholecystokinin (CCK), neurotensin
- Receptors: Mu, delta, and kappa opioid receptors, 5-HT1A/1B serotonin receptors, NMDA and AMPA glutamate receptors
The PAG is a critical node in the descending pain modulatory system:
- Pain inhibition: Activation of vlPAG triggers downstream release of serotonin and norepinephrine in the spinal cord dorsal horn, inhibiting pain transmission [4]
- Opioid analgesia: Mu opioid receptors in the PAG mediate both endogenous and exogenous opioid analgesia
- Pain facilitation: The PAG also contributes to pain facilitation under certain conditions, particularly in chronic pain states
- Resting membrane potential: -55 to -70 mV
- Action potential: Typically 1-2 ms duration
- Firing patterns: Mix of tonic firing, burst firing, and pause-build patterns
- Synaptic plasticity: Long-term potentiation (LTP) and depression (LTD) at PAG synapses
¶ Afferent and Efferent Connections
- Hypothalamus: Preoptic area, paraventricular nucleus for autonomic integration
- Amygdala: Central nucleus for emotional processing
- Prefrontal cortex: Cognitive modulation of pain and emotions
- Somatosensory cortex: Sensory-discriminative pain aspects
- Spinal cord: Nociceptive information via spinomesencephalic tract
- Rostral ventromedial medulla (RVM): Serotonergic and nociceptive modulation of spinal cord
- Nucleus of the solitary tract (NTS): Autonomic reflex integration
- Parabrachial nucleus: Visceral sensory processing
- Thalamus: Sensory and emotional aspects of pain
- Hypothalamus: Neuroendocrine and autonomic responses
The PAG coordinates endogenous pain control through:
- Activation of descending inhibitory pathways to the spinal cord dorsal horn
- Release of endogenous opioids (enkephalins, dynorphins) and serotonin
- Modulation of sensory gating at multiple CNS levels
The PAG integrates emotional and autonomic responses:
- Fear responses: vlPAG activation triggers freezing and flight behaviors
- Anxiety: dlPAG involvement in anxiogenic behaviors
- Pleasure: Opioid receptor activation produces euphoria and reward
- Vocalization: PAG coordinates vocal output during emotional states
- Cardiovascular regulation through RVM and NTS projections
- Respiratory modulation
- Bladder control
- Gastrointestinal motility regulation
-
Pain abnormalities: PD patients frequently experience chronic pain, often with altered PAG function. Studies show reduced PAG activation in response to pain stimuli in PD [5][6].
-
Emotional processing: Depression and anxiety in PD involve dysregulation of PAG-limbic circuits.
-
Autonomic dysfunction: Orthostatic hypotension, urinary dysfunction, and thermoregulatory impairment in PD involve PAG-brainstem pathways.
-
Falls and posture: PAG involvement in postural control contributes to falls in PD.
-
Pain processing alterations: AD patients show altered pain perception and reduced analgesic responses, possibly involving PAG dysfunction [7].
-
Emotional and behavioral symptoms: Agitation, anxiety, and depression in AD involve disrupted PAG-limbic circuitry.
-
Neuroanatomical changes: Post-mortem studies show PAG involvement in AD pathology, including neurofibrillary tangle deposition.
-
Emotional processing deficits: HD patients show impaired emotional recognition and altered PAG responses to emotional stimuli [8].
-
Pain perception: Abnormal pain thresholds in HD may involve PAG dysfunction.
-
Autonomic dysfunction: Dysautonomia in HD includes cardiovascular irregularities consistent with PAG involvement.
-
Pain processing: ALS patients experience various pain syndromes with possible PAG involvement.
-
Respiratory control: PAG projections to brainstem respiratory centers may contribute to respiratory dysfunction in ALS.
- Opioid analgesics: Act on PAG mu opioid receptors for pain management
- Antidepressants: SSRIs and SNRIs modulate PAG serotonergic pathways
- Deep brain stimulation: PAG-DBS for treatment-resistant pain
- Targeted drug delivery: Agents targeting specific PAG receptor subtypes
- Gene therapy: AAV-mediated delivery of neurotrophic factors to PAG neurons
- Transcranial magnetic stimulation: Non-invasive PAG modulation
- Cell transplantation: Experimental approaches to restore PAG function
- Bandler R et al., Midbrain periaqueductal gray (2000)
- Behbehani MM, Functional characteristics of the midbrain periaqueductal gray (1995)
- Millan MJ, Descending control of pain (2002)
- Fields HL, Pain modulation: expectation, opioid analgesia and virtual pain (2000)
- Chaudhuri KR & Schapira AH, Non-motor symptoms of Parkinson's disease (2009)
- Wen MC et al., Pain in Parkinson's disease (2017)
- Scherder EJ et al., Pain in Alzheimer's disease (2005)
- Huntington's Disease Society of America, Clinical characteristics of HD (2020)